Abstract
Marine algae’s, owing to diverse range of secondary metabolites, opening up the new avenues in new drug development and can be used efficiently in anticancer research. Two seaweeds Gracilaria foliifera and Turbinaria conoides are subjected to phytochemical investigation by HR-LCMS and NMR which confirms presence of different bioactive compounds. The cytotoxicity of the dichloromethane (DCM) fraction of Gracilaria foliifera and Turbinaria conoides was determined using an in vitro methyl thiazolyl tetrazolium (MTT) test and showed considerable dose-dependent cytotoxicity on tumour cell lines. In MCF7, Gracilaria foliifera had an IC50 of 100 μg/ml, while Turbinaria conoides had an IC50 of 200 μg/ml and both the DCM fraction had IC50 values of 100 μg/ml in the A549 cell line. MTT assay for anticancer activity suggest that Gracilaria foliifera has potent anticancer activity in both breast and lung cell lines, while the DCM fraction of Turbinaria conoides has potent activity in lung cell lines and moderate activity in breast cell lines. The anticancer effects of the discovered drugs targeting the most prevalent enzymes VEGFR and AXL tyrosine kinases were confirmed using a computational technique. We believe that residues from VEGFR, like Lys868, Asn923, Asp1046, and Phe1047 and Asp690 from Axl kinase may have contributed to the plausible anti-cancer benefit seen in this study. Communicated by Ramaswamy H. Sarma
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
